Oak Crest Institute of Science Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial
2015
NCT02431273
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Oak Crest Institute of Science

Active Ingredients

Drugs in Phase 1 Trials (3)

emtricitabine (emtriva) (1 trial)

maraviroc (selzentry) (1 trial)

tenofovir (viread) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 1)

HIV Infections (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 3